Australia - inglés - Department of Health (Therapeutic Goods Administration)

dukehill healthcare pty ltd - 63693 - urinary catheter ultrasonic bacterial adhesion inhibition system actuator - the uroshield actuator is attached onto the urinary catheter after the catheter is inserted into the patient. the actuator is active when attached to the uroshield driver. the actuator is intended for single patient use and should be changed with each catheter change.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

dukehill healthcare pty ltd - 63691 - urinary catheter ultrasonic bacterial adhesion inhibition system - ?the uroshield? system is intended to prevent bacterial biofilm formation by generating ultrasound waves on the inner and outer surfaces of the catheter. the waves interfere with the attachment of bacteria (which is the initial step in biofilm formation) and increase antibiotic efficacy against biofilm bacteria. by means of the ultrasound waves that mitigate against biofilm formation, the uroshield? also reduces friction between the catheter and the patient?s internal tissues this helps to decrease the pain, discomfort and spasm associated with indwelling urinary catheters. the uroshield? driver is a low-energy, mains and battery powered medical device that supplies electrical signals to the actuator. the uroshield? actuator is attached onto the urinary catheter after the catheter is inserted into the patient. the actuator is intended for single patient use only

Canadá - inglés - Health Canada

pendopharm division of pharmascience inc - cetirizine hydrochloride - tablet - 5mg - cetirizine hydrochloride 5mg - second generation antihistamines

Canadá - inglés - Health Canada

pendopharm division of pharmascience inc - cetirizine hydrochloride - tablet - 10mg - cetirizine hydrochloride 10mg - second generation antihistamines

Canadá - inglés - Health Canada

pendopharm division of pharmascience inc - cetirizine hydrochloride - tablet - 20mg - cetirizine hydrochloride 20mg - second generation antihistamines

Unión Europea - inglés - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing ltd - imidacloprid, moxidectin - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme).the veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (fad). for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis). for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis).the veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (fad).

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nestle purina petcare a div of nestle australia ltd - fipronil - topical solution/suspension - fipronil nitrile active 100.0 g/l - parasiticides

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nestle purina petcare a div of nestle australia ltd - fipronil - topical solution/suspension - fipronil nitrile active 100.0 g/l - parasiticides

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - levetiracetam 1000mg - film coated tablet - 1000 mg - active: levetiracetam 1000mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry white 85f18422 povidone purified talc - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - levetiracetam 250mg - film coated tablet - 250 mg - active: levetiracetam 250mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry blue 85f20694 povidone purified talc - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).